Daclizumab versus anti-thymocyte globulin-fresenius as induction therapy for low-risk kidney transplant recipients

Transplant Proc. 2003 Nov;35(7):2731-2. doi: 10.1016/j.transproceed.2003.08.043.
No abstract available

Publication types

  • Clinical Trial
  • Comparative Study
  • Controlled Clinical Trial

MeSH terms

  • Adult
  • Antibodies / blood
  • Antibodies, Monoclonal / adverse effects*
  • Antibodies, Monoclonal / therapeutic use
  • Antibodies, Monoclonal, Humanized
  • Antilymphocyte Serum / adverse effects
  • Antilymphocyte Serum / therapeutic use*
  • Creatinine / blood
  • Daclizumab
  • Female
  • Follow-Up Studies
  • Graft Rejection / epidemiology
  • Humans
  • Immunoglobulin G / adverse effects*
  • Immunoglobulin G / therapeutic use
  • Immunosuppressive Agents / adverse effects
  • Immunosuppressive Agents / therapeutic use
  • Kidney Transplantation / immunology*
  • Lipids / blood
  • Male
  • Middle Aged
  • Patient Selection
  • Time Factors

Substances

  • Antibodies
  • Antibodies, Monoclonal
  • Antibodies, Monoclonal, Humanized
  • Antilymphocyte Serum
  • Immunoglobulin G
  • Immunosuppressive Agents
  • Lipids
  • Creatinine
  • Daclizumab